To compare etiologies of prolonged amenorrhea in a cohort of HIV-infected women with a cohort of similar uninfected at-risk women.
Materials and Methods:
Women from the Women's Interagency HIV Study were seen every 6 months, and completed surveys including questions about their menstruation. Those who reported no vaginal bleeding for at least 1 year (“prolonged amenorrhea”) with subsequent resumption of bleeding were compared with women in whom bleeding had stopped permanently (“menopause”). Characteristics associated with reversible prolonged amenorrhea were ascertained.
Results:
Of 828 women with prolonged amenorrhea, 37.6% had reversible amenorrhea and 62.4% never resumed menses. HIV-seropositive women with prolonged amenorrhea were significantly younger at cessation of menses than HIV-negative women (p < 0.0001). Of those with reversible prolonged amenorrhea, approximately half were taking medications associated with amenorrhea, including 95 (30.6%) hormonal contraception, 80 (25.7%) opiates/stimulants, 16 (5.1%) psychotropic medications, and 6 (1.9%) chemotherapy. HIV-seropositive women were less likely to have medications as a cause of amenorrhea than seronegative women (p = 0.02). In multivariable analysis, women with reversible prolonged amenorrhea of unknown etiology were younger (p < 0.0001), more often obese (p = 0.03), and less educated (p = 0.01) than those with permanent amenorrhea. Among HIV-seropositive women, markers of severe immunosuppression were not associated with prolonged amenorrhea.
Conclusion:
Women with HIV infection have unexplained prolonged amenorrhea more often than at-risk seronegative women. This is especially common among obese, less-educated women. Prolonged amenorrhea in the HIV-seropositive women should be evaluated and not be presumed to be to the result of menopause.
Get full access to this article
View all access options for this article.
References
1.
LohseN, HansenAB, GerstoftJ, ObelN. Improved survival in HIV-infected persons: Consequences and perspectives. J Antimicrob Chemother, 2007; 60:461–463.
2.
Centers for Disease Control and Prevention. HIV among people aged 50 and over, 2018. Available at: www.cdc.gov/hiv/group/age/olderamericans/index.html Updated February12, 2018. [Accessed February14, 2018].
3.
HighKP, Brennan-IngM, CliffordDB, et al.HIV and aging: State of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr, 2012; 60:s1–s18.
4.
AdamGP, DiM, Cu-UvinS, et al.Strategies for improving the lives of US women aged 40 and above living with HIV/AIDS: An evidence map. Syst Rev, 2018; 7:25.
5.
GrinspoonS, CorcoranC, MillerK, et al.Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab, 1997; 82:1332–1337.
6.
ClarkRA, CohnSE, JarekC, et al.Perimenopausal symptomatology among HIV-infected women at least 40 years of age. J Acquir Immune Defic Syndr, 2000; 23:99–100.
7.
SchoenbaumEE, HartelD, LoY, et al.HIV infection, drug use, and onset of natural menopause. Clin Infect Dis, 2005; 41:1517–1524.
8.
BrombergerJT, MatthewsKA, KullerLH, WingRR, MeilahnEN, PlantingaP. Prospective study of the determinants of age at menopause. Am J Epidem, 1997; 145:124–133.
9.
CejtinHE, KalinowskiA, BacchettiP, et al.Effects of human immunodeficiency virus on protracted amenorrhea and ovarian dysfunction. Obstet Gynecol, 2006; 108:1423–1431.
10.
SeiferDB, GolubET, Lambert-MesserlianG, et al.Biologic markers of ovarian reserve and reproductive aging: Application in a cohort study of HIV infection in women. Fertil Steril, 2007; 88:1645–1652.
11.
MassadLS, EvansCT, MinkoffH, et al.Effects of HIV infection and its treatment on self-reported menstrual abnormalities in women. J Womens Health, 2006; 15:591–594.
12.
TariqS, DelpechV, AndersonJ. The impact of the menopause transition on the health and wellbeing of women living with HIV: A narrative review. Maturitas, 2016; 88:76–83.
13.
ImaiK, SuttonMY, MdodoR, Del RioC. HIV and menopause: A systematic review of the effects of HIV infection on age at menopause and the effects of menopause on response to antiretroviral therapy. Obstet Gynecol Int, 2013; 2013:340309.
14.
AndanyN, KennedyVL, AdenM, LoutfyM. Perspectives on menopause and women with HIV. Int J Womens Health, 2016; 8:1–22.
15.
HeimanDL. Amenorrhea. Prim Care, 2009; 36:1–17.
16.
WHO Scientific Group on Research on the Menopause in the 1990s. WHO Technical Report Series Geneva, Switzerland: WHO, 1996.
17.
De VosM, DevroeyP, FauserBC. Primary ovarian insufficiency. Lancet, 2010; 376:911–921.
18.
HillardPA. Menstrual suppression: Current perspectives. Int J Womens Health, 2014; 6:631–637.
19.
BergaS, NaftolinF. Neuroendocrine control of ovulation. Gynecol Endocrinol, 2012; 28Suppl 1:9–13.
20.
SobieszczykME, HooverDR, AnastosK, et al.The Women's Interagency HIV Study. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr, 2008; 48:272–280.
21.
ViganoA, ManzoniP, RivaS, BrambillaP, FerrazziE, MarziMM. Hyperinsulinemia induced by highly active antiretroviral therapy in an adolescent with polycystic ovary syndrome who was infected with human immunodeficiency virus. Fertil Steril, 2003; 79:422–423.
22.
YoganathanKT, SadiqS, YoganathanKG. An unusual cause of isolated secondary ovarian failure due to cerebral toxoplasmosis in an African woman with AIDS. BMJ Case Rep, 2017Aug7; 2017. pii: bcr-2017-221337. DOI: 10.1136/bcr-2017-221337.
23.
BarkanSE, MelnickSL, Preston-MartinS, et al.The Women's Interagency HIV Study. Epidemiology, 1998; 9:117–125.
24.
BaconMC, von WylV, AldenC, et al.The Women's Interagency HIV Study: An observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol, 2005; 12:1013–1019.
25.
ScherzerR, BacchettiP, MesserlianG, et al.Impact of CD4+ lymphocytes and HIV infection on anti-mullerian hormone levels in a large cohort of HIV-infected and HIV-uninfected women. Am J Reprod Immunol, 2015; 73:273–284.
26.
HubacherD, LopezL, SteinerM, DorfingerL. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: A systematic review and evidence-based comparisons. Contraception, 2009; 80:113–118.
27.
KantartzisKL, SucatoGS. Menstrual suppression in the adolescent. J Pediatr Adolesc Gynecol, 2013; 26:132–137.
28.
MillerL, HughesJP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: A randomized trial. Obstet Gynecol, 2003; 101:853–881.
29.
CooperOB, BrownTT, DobsAS. Opiate drug use: A potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease. Clin Infect Dis, 2003; 37:132–136.
30.
FantryLE, ZhanM, TaylorGH, SillAM, FlawsJA. Age of menopause and menopausal symptoms in HIV-infected women. AIDS Patient Care STDS, 2005; 19:703–711.
CofrancescoJJr., ShahN, GhanemK, et al.The effects of illicit drug use and HIV infection on sex hormone levels in women. Gynecol Endocrinol, 2006; 22:244–245.
HarlowSD, CohenM, OhmitSE, et al.Substance use and psychotherapeutic medications: A likely contributor to menstrual disorders in women who are seropositive for human immunodeficiency virus. Am J Obstet Gynecol, 2003; 188:881–886.
35.
SukumvanichP, CaseLD, Van ZeeK, et al.Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: A prospective study. Cancer, 2010; 116:3102–3111.
36.
LiuJH, BillAH. Stress-associated or functional hypothalamic amenorrhea in the adolescent. Ann N Y Acad Sci, 2008; 1135:179–184.
37.
IckovicsJ, HamburgerME, VlahavD, et al.Mortality, CD4 cell count decline and depressive symptoms among HIV-seropositive women: Longitudinal analysis from the HERS. JAMA, 2001; 285:1466–1474.
38.
CohenM, HoffmanRG, CromwellC, et al.The prevalence of distress in persons with human immunodeficiency virus infection. Psychosomatics, 2002; 43:10–15.
39.
SchoenakerD, JacksonCA, RowlandsJV, MishraGD. Socioeconomic position, lifestyle factors and age at natural menopause: A systematic review and meta-analyses of studies across six continents. Int J Epidemiol, 2014; 43:1542–1562.
40.
MishraGD, CooperR, TomSE, KuhD. Early life circumstances and their impact on menarche and menopause. Womens Health, 2009; 5:175–190.
41.
RuthKS, PerryJRB, HenleyWE, MelzerD, WeedonMN, MurrayA. Events in early life are associated with female reproductive ageing: A UK biobank study. Sci Rep, 2016; 6:24710.
42.
CalvetGA, GrinsztejnBG, Quintana MdeS, et al.Predictors of early menopause in HIV-infected women: A prospective cohort study. Am J Obstet Gynecol, 2015:212:765e1–13.
43.
CicconiP, AmmassariA, LadisaN, et al.DIDI Study Group. Prevalence of prolonged amenorrhea in HIV-infected women: Results from the Italian DIDI study. J Acquir Immune Defic Syndr, 2012; 61:e19–e21.
44.
NansseuJR, BionaJJ, KazaAD, NoubianJJ. Incidence and risk factors for prediabetes and diabetes mellitus among HIV infected adults on antiretroviral therapy: Systematic review and meta-analysis. Epidemiology, 2018; 29:431–441.
45.
PignyP, JonardS, RobertY, DewaillyD. Serum anti-Mullerian hormone as a surrogate for antral follicle count for the definition of polycystic ovary syndrome. J Clin Endocrinol Metab, 2006; 91:941–945.
46.
SkalbaP, CygalA, MadejP, et al.Is the plasma anti-Mullerian hormone (AMH) level associated with body weight and metabolic, and hormonal disturbances in women with and without polycystic ovary syndrome?. Eur J Obstet Gynecol Reprod Biol, 2001; 158:254–259.
47.
ScherzerR, GreenblattRM, MerhiZO, et al.Use of antimullerian hormone to predict the menopausal transition in HIV-infected women. Am J Obstet Gynecol, 2017; 216:46.e1-11.
48.
KojicEM, WangC, Cu-UvinS. HIV and menopause: A review. J Womens Health, 2007; 16:1402–1411.
49.
GoodmanNF, CobinRH, FuttenweitW, GlueckJS, LegroRS, CarminaE. American Association of Clinical Endocrinologists (AACE): American College of Endocrinology ACE); Androgen Excess and PCOS Society: Guide to the best practices in the evaluation and treatment of polycystic ovary syndrome-Part 2. Endocr Pract, 2015; 21:1415–1426.
